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Summary
Background: Reactivation of latent varicella-zoster virus in sensory neurons to cause herpes
zoster (shingles) is common in adults 50 years of age and older; half of adults experience
an episode by age 85 years. Herpes zoster is attributable to the progressive decline in the
VZV-specific cell-mediated immunity that occurs with aging or other conditions that cause
immune compromise. Herpes zoster and complications, such as postherpetic neuralgia (PHN),
can have a substantial negative impact on quality of life.
Discussion: The incidence of herpes zoster and its associated morbidity is increasing worldwide
as the population ages. Nevertheless, the severity and impact of this condition, and its painful
sequelae, are often unrecognized. Many patients delay seeking medical attention, complicating
both diagnosis and treatment. Prevention appears to be the best option. A new herpes zoster
vaccine significantly reduced the burden of illness (61.1%), the incidence of PHN (66.5%), and
the incidence of herpes zoster (51.3%) (p < 0.001). Vaccine tolerability was good, with minor
local injection site reactions the most common adverse event.
Conclusions: Herpes zoster and PHN represent a substantial burden in terms of suffering and
associated costs. Immunization of older adults is a good option to prevent herpes zoster and
PHN.
© 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Introduction
The vast majority of adults are likely to have been infected
with the varicella-zoster virus (VZV). The initial infection
causes chicken pox, usually in childhood.1 Subsequently,
VZV remains latent in sensory ganglia for life. Symptomatic
* Corresponding author: Dr. Robert Johnson, 9 Ridgeway Road,
Long Ashton, Bristol, UK, BS41 9EX. Tel.: +44-1275-393104.
E-mail address: r.w.johnson@bris.ac.uk
1201-9712/$32.00 © 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
reactivation of VZV as herpes zoster, also called shingles,
is a common age-related disease, affecting up to half of
all adults who live to 85 years of age.2,3 Reactivation is
attributed to the natural immunosenescence that occurs
with aging, as well as to other conditions that cause
immunocompromise.4- 8
Studies worldwide document that the incidence, sever-
ity, and complications of herpes zoster all increase with
age.3,9- 13 Historic data show a consistent upward trend in
the incidence of herpes zoster.5,10 As the elderly population
increases, the number of people affected by herpes zoster
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will increase.2,14 This is important because the manage-
ment of herpes zoster and its complications is associated
with a large economic burden. A U.K. study exemplified
the high costs involved in both acute care and treatment of
complications, with the highest medical costs for patients
65 years of age and older.15
Despite the widespread nature of this disease, rapid,
early diagnosis is sometimes problematic because it relies
primarily on the appearance of the typical rash.3,9 Differ-
ential diagnosis during the prodromal phase involves ruling
out other causes of localized pain, such as trauma, myocar-
dial ischemia, renal colic, gallbladder disease, dental pain,
and pleurisy.9 The nature of the symptoms is such that
acute treatment is often delayed because patients either
wait to seek treatment or remain undiagnosed while other
conditions are ruled out.8,9 Antiviral agents are partially
effective in reducing acute pain, hastening rash resolu-
tion and shortening the duration of pain. These are well
tolerated and most effective when offered early, but the
diagnosis is often delayed beyond the 72-hour window of
opportunity for optimal treatment effect.9
Following the acute disease phase, herpes zoster can
be associated with severe complications and morbidities
that reduce functioning and quality of life. Complications
occur in at least half of all older patients affected by
herpes zoster.5,7 Postherpetic neuralgia (PHN) is the most
common and most feared of these complications, and
can cause an otherwise high functioning elderly patient
to become debilitated.1,8,16,17 Treating PHN is difficult be-
cause no therapy is predictably effective, treatment is
time consuming, and side effects and drug interactions
are especially common in older patients receiving multiple
medications.9,14
We review the epidemiology and natural history of
herpes zoster, emphasizing its impact on patients and the
difficulties involved in case management. Given the diffi-
culties with rapidly diagnosing herpes zoster and treating
its painful, debilitating sequelae, prevention through vac-
cination is discussed as the most promising option currently
available.
Figure 1 The incidence of herpes zoster is consistent, worldwide.10,20- 22,45- 47
Epidemiology
Herpes zoster
Primary infection with VZV causes varicella, which usu-
ally occurs in children in temperate climates, but also in
adolescents and adults in tropical areas. Following this
infection, VZV remains latent in sensory ganglia. Latent
virus can reactivate, often 4 to 5 decades later, to pro-
duce herpes zoster.8 The mechanism of latency is poorly
understood, but it is clear that some minimal level of
VZV-specific immunity is required to maintain VZV in its
latent state. A decline in this immunity, such as occurs in
patients with immunosuppressive illnesses or therapies, is
associated with a large increase in the incidence of herpes
zoster.3,18 Moreover, a significant decrease in VZV-specific
cellular immunity (but not in VZV antibody), which is a nat-
ural consequence of aging, explains why VZV reactivation
and the resulting herpes zoster is associated with aging.
Although reactivation also occurs in younger people who
do not have immunocompromising conditions, their risk for
complications of shingles is diminished.4,9
The incidence of herpes zoster increases significantly
with age, with 67% of cases occurring in persons over 50
years of age.12 This was shown in a U.K. study (1947---62)
in which the annual incidence of herpes zoster was 7.8 per
1000 persons in patients over 60 years of age compared
with an overall annual incidence of 3.4 per 1000 persons.10
A more recent study demonstrated a correlation between
increasing herpes zoster incidence and age, where inci-
dence rates of 1.9 to 3.1 per 1000 were observed in
patients younger than 55 years of age, compared with
11.8 per 1000 person years in patients older than 65
years.19 This translates to a large at-risk population5,9,20
that is remarkably consistent worldwide (Figure 1).10,20- 24
Up to 800,000 cases of herpes zoster occur annually in the
U.S.,11 for a lifetime incidence of up to 20% in the general
population.3 The lifetime risk in Europe is between 23 and
30%.13,21,25 Approximately 90% of adults in the European
Union have had chickenpox, so that 1.8 million new cases
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of herpes zoster would be expected each year, assuming a
population of 460 million.10,26,27 Annual rates for patients
of all ages in Europe have been reported as 4.14/1000 in
Italy,23 4/1000 in France,24 3.56 in the United Kingdom,22
3.30 in the Netherlands,20 and 2.26/1000 in Germany.28
PHN
An age-associated increase in the prevalence of PHN is
characteristic of herpes zoster.9 The proportion of patients
with herpes zoster who develop PHN increases rapidly from
age 50.10 While there is no consensus on a definition for
PHN, it is commonly defined as pain persisting at least 1 to
3 months after the onset of the herpes zoster rash.14 Given
this definition, 20% of all patients 50 years of age and older
who have herpes zoster will develop PHN.9,13,14,29
The risk of PHN, as defined above, increases dramati-
cally with age; 3% to 4% of adults 30 to 49 years old, 21%
of those 60 to 69 years of age, 29% of those 70---79 years
of age, and 34% in those over 80 years develop PHN.10 This
translates to a 14.7-fold higher prevalence of pain 30 days
after rash onset and a 27.4-fold higher prevalence 60 days
after rash onset in patients at least 50 years of age when
compared with younger patients.30
Natural history
VZV-specific antibody, which does not decline with age,
is the primary defense against the host developing chick-
enpox again after re-exposure to VZV. VZV-specific cell-
mediated immunity, which declines with age and immune
compromise, is the defense against herpes zoster. This
immunity is boosted exogenously when a person is exposed
to children with varicella, and endogenously by sub-clinical
reactivation. The frequency of recurrent herpes zoster
in immunocompetent individuals is low, 1.7% to 5.2%,
probably because a single episode of herpes zoster re-
sults in a very strong boost in VZV-specific cell-mediated
immunity.1,31
Figure 2 PHN has a substantial impact on quality of life. Greater pain burden has been associated with decreased physical, role, and
social functioning, as well as increased emotional distress in the form of depression and psychological impairment.37
Clinical features of herpes zoster include pain and
paresthesia, in a dermatomal distribution, that may pre-
cede the rash by up to 4 days, with a range of symptoms
from itching to severe lancinating pain. Constitutional
symptoms such as fever, headache, or malaise may also
occur.7,8,14,18,29,32 Herpes zoster most commonly localizes
to the thoracic region (50---62%), followed by the cranial
region --- which includes ophthalmic zoster (12---21%) --- the
lumbar (10---14%), cervical regions (11---14%), and the sacral
region (2---8%).6,10,33,34
Complications of herpes zoster
PHN is the most common complication of herpes zoster,35
involving the peripheral and central nervous system.36 Risk
factors for PHN include greater age, severity of acute pain,
extent of rash, presence of prodromal pain, and, possibly,
concomitant disease such as diabetes, which could be due
to preexisting neuropathy.36 The PHN manifestations can
be steady, throbbing or burning pain, spontaneous, con-
stant or intermittent pain, that can be sharp or shooting,
and allodynia (pain from stimuli that are not normally
painful).36 The duration and severity of zoster-associated
pain increases with age (Figure 2).37
PHN treatment requires a multifaceted approach.7,16
Treatment is difficult because the symptoms and mech-
anisms vary between patients, and medical management
of chronic neuropathic pain is challenged by comorbidities
and susceptibility to cognitive decline that increase the risk
for drug adverse effects and drug-drug and drug-disease
interactions. Psychosocial issues may also complicate pain
management and often have functional and affective
consequences.38
Impact on quality of life
World Health Organization data suggest that while medical
advances have resulted in prolongation of life, the gap
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that still exists between morbidity and disability lowers
the quality of life for older people. Instead of dying earlier,
people are living longer with disability.39,40 The develop-
ment of herpes zoster and PHN in older adults is likely
to lead to extended periods of restricted activity and bed
rest, further complicating the disease and underlying dis-
ease process, and contributing to disability and functional
decline.41,42
Much of the personal disability and reduced quality of
life associated with herpes zoster and PHN may not be
captured in studies that focus on work days lost or length
of hospital stay due to the chronicity of the disease.
Severe or longer-lasting pain continues to impair quality
of life after the acute event.16 Specifically, patients with
a greater herpes zoster pain burden have poorer physical
functioning, increased emotional distress, and decreased
role and social functioning.16 Approximately 30% of older
patients with herpes zoster (mean age 70 years) reported
interference with activities of daily living (general, work,
sleep, enjoyment), and 70% noted interference at a pain
level indicative of marked interference with activities of
everyday living.17
Challenges in treating herpes zoster and PHN
Treatment of herpes zoster may be sub-optimal because of
delayed or atypical presentation.2,9 Antivirals can alleviate
acute pain and the duration of long-term pain. It remains
controversial as to whether antivirals reduce the incidence
of persistent PHN.
Corticosteroids also have beneficial effects on acute
pain, but no effect on preventing PHN.30,35 Pain medica-
tions are difficult to use in an optimal fashion, especially in
the elderly, in whom side effects or drug interactions may
limit their utility.2,9 Current management of PHN relies on
oral medication from one of three groups of drugs either
alone or in combination. The tricyclic antidepressant drugs
(e.g. nortriptyline, amitriptyline, desipramine) have simi-
lar efficacy to both alpha-2 delta ligands (e.g. gabapentin,
pregabalin) and strong opioids (e.g. morphine, oxycodone).
The choice of first line drug will depend upon the status of
an individual patient but there is no evidence to indicate
that choice may be made according to pain mechanism as
suggested by the patient' s particular symptoms and signs.
Topical lidocaine can be effective as adjunctive therapy
and some patients tolerate and gain benefit from capsaicin
cream. Probably less than half of patients gain 50% benefit
from treatment. It should be remembered that response
to pain has psychosocial as well as biological components
and encouraging patients to remain as active as possible
will limit the disabling complications of zoster and PHN.
A single, non-replicated, study of intrathecal injection of
methylprednisolone suggested significant benefit but there
are concerns about long term safety.43,44
Prevention of herpes zoster
Prevention through vaccination is the most promising ap-
proach to the problem of herpes zoster and its severe
complications.3,8,35 The new herpes zoster vaccine is a
live, attenuated cell-free preparation of the Oka/Merck
strain of VZV.26 Attenuated by passages in tissue culture, it
contains whole live virus, viral antigens, and several inert
ingredients. The rationale for developing a vaccine was
to boost VZV-specific cell-mediated immunity and thereby
prevent or attenuate both herpes zoster and PHN.
The Shingles Prevention Study
The Shingles Prevention Study was undertaken to deter-
mine whether immunization with this live, attenuated
zoster vaccine would reduce the incidence or severity of
herpes zoster and PHN in patients at least 60 years of
age.26 This double blind, placebo controlled trial random-
ized 38,546 patients at 22 U.S. sites, stratifying patients by
medical center and age (60---69 years vs. ≥70 years). The
primary efficacy endpoint was the herpes zoster “Burden
of Illness” score and incidence of PHN was a secondary
endpoint. The Burden of Illness score captures in one mea-
surement the incidence, severity, and duration of herpes
zoster in each treatment arm of the study. Herpes zoster
incidence was an additional measurement. The average
Figure 3 Immunization reduced: (a) herpes zoster burden of ill-
ness by 61.1% (p < 0.001 versus placebo), (b) incidence of PHN by
66.5%, and (c) incidence of herpes zoster by 51.3%.26
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duration of surveillance was 3.1 years, with a maximum
follow-up of 4.9 years.
A 61.1% reduction in Burden of Illness was observed (p <
0.001 vs. placebo; 95% CI 51.1---69.1) (Figure 3a). Greater
decreases in the vaccinated subjects were observed with
respect to the worst pain (Burden of Illness scores ≥ 600),
so that the vaccine greatly reduced the number of patients
with the most pain (11 versus 40). Significant reductions in
the incidence of PHN (66.5%; 95% CI 47.5---79.2) and herpes
zoster (51.3%; 95% CI 44.2---57.6) were also observed (p <
0.001 vs. placebo) (Figures 3b and c). Reduced efficacy was
observed with regards to herpes zoster incidence among
patients 70 years of age and older (37.5% reduction),
but these patients still benefited significantly from lower
Burden of Illness scores (55.4% reduction) and lower PHN
incidence (66.8% reduction).
The safety of the vaccine was similar to that of the
placebo in the overall population safety analysis. In the
vaccine group 255 of 19,270 (1.37%) patients and 254 of
19,276 (1.36%) in the placebo group experienced serious
adverse events. From these serious adverse events, only
two were considered vaccine-related in the vaccine group
and three in the placebo group. A safety sub-study provided
detailed assessments of 6616 patients. In this sub-study, lo-
cal injection-site adverse events were the most commonly
reported (48.3% vaccine group versus 16.6% placebo group;
p < 0.05), while a similar percentage of patients experi-
enced a systemic adverse event (24.7% of patients in the
vaccine group versus 23.6% in the placebo group). Vaccine-
related systemic adverse events were experienced by 6.3%
patients in the vaccine group and 4.9% in the placebo group
(p < 0.05), headache being the most frequently reported
(1.4% versus 0.9% respectively, p < 0.05).
Conclusions
Herpes zoster is a very common disease that can be severe.
The impact of herpes zoster on older patients is not fully
appreciated by some physicians. Herpes zoster can some-
times have devastating consequences on patient quality
of life, particularly when PHN develops. Herpes zoster
incidence has been remarkably consistent over time and
throughout the world. Given the severity of disease and
the considerable lifetime risk, more effective management
of herpes zoster and PHN is essential. Over the past 20
years there has been progress in compressing morbidity to
the very end of life through improved diet, exercise, and
healthcare. The next challenge will be to postpone disabil-
ities due to aging by using strategies such as vaccination
to prevent diseases common in elderly patients. Prevention
of herpes zoster and PHN should be one important goal for
promoting healthy aging.
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